Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Crohn's Disease

This page shows the latest Crohn's Disease news and features for those working in and with pharma, biotech and healthcare.

Lilly reports positive data from its phase 3 ulcerative colitis trial

Lilly reports positive data from its phase 3 ulcerative colitis trial

Ulcerative colitis can be debilitating and unpredictable for the hundreds of thousands of people living with this chronic disease," said Caren Heller, chief scientific officer for the Crohn's &Colitis Foundation. ... Lilly is also studying mirikizumab in

Latest news

  • Homesick Homesick

    susceptible are those with underlying co-morbidities like metabolic syndrome and cardiovascular disease. ... And then we have a whole ‘other’ group – patients with psoriasis, rheumatoid arthritis, Crohn’s disease, and also oncology patients.

  • AbbVie says Allergan takeover delayed by FTC verdict AbbVie says Allergan takeover delayed by FTC verdict

    position. There’s no specified timeline for that review to complete, but AbbVie says it has “entered into a timing agreement with FTC staff that would likely result” in a ... AZ licensed the drug – which is in late-stage testing for ulcerative

  • After FDA refusal, Takeda builds case for subcutaneous Entyvio After FDA refusal, Takeda builds case for subcutaneous Entyvio

    Intravenous Entyvio is already available in 60 countries. Takeda has reported updated results from a trial of its subcutaneous formulation of Entyvio in Crohn’s disease, showing activity over a year ... An enhanced clinical response rate – defined as

  • AbbVie lauds head-to-head win for Skyrizi versus Cosentyx AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

    according to AbbVie outperformed its rival across all the trial’s primary and secondary outcome measures. ... It also has registration trials for Skyrizi ongoing in Crohn's disease and ulcerative colitis due to generate results next year, as well as

  • Takeda’s subcutaneous Entyvio formulation faces FDA rejection Takeda’s subcutaneous Entyvio formulation faces FDA rejection

    treatments. It also indicated for use in adult patients with moderate-to-severe active Crohn’s Disease who have similarly had inadequate responses to standard treatments. ... after a lead-in period, were in remission from the inflammatory bowel disease

More from news
Approximately 20 fully matching, plus 153 partially matching documents found.

Latest Intelligence

  • Gut instincts lead Takeda to GI pipeline success Gut instincts lead Takeda to GI pipeline success

    with Crohn’s disease or ulcerative colitis is expected to rise by around 25% by 2025, according to recent studies. ... This will help physicians take much better care of patients for something that is a lifetime disease.”.

  • Case study: 4 Sites – Navigating the course ahead Case study: 4 Sites – Navigating the course ahead

    Client:SCITERION. Agency:N/A. Campaign:4 Sites: Navigating the course ahead. Timescale:N/A. Crohn’s disease – a chronic, debilitating and progressive disease – is on the increase worldwide, but remission

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The first test of this will be Shire’s new blockbuster-in-waiting Takhzyro, which gained EMA approval in November, for the rare disease hereditary angioedema (HAE). ... Boehringer Ingelheim) for psoriatic arthritis, Crohn’s disease and other

  • Deal Watch October 2018

    Collaboration for. development. $760m. Enterome/. Takeda. EB8018 for Crohn’s disease and other gastrointestinal. ... Roche has an existing agreement with Ionis for IONIS‐HTTRx, an antisense drug for Huntington’s Disease, and the new deal is to

  • Innovation in merger control and the impact on the pharmaceutical sector Innovation in merger control and the impact on the pharmaceutical sector

    Pipeline problems. The Commission’s novel approach has its roots in pharma mergers. ... Specifically, Hospira was selling Inflectra, an infliximab biosimilar used to treat several chronic inflammatory diseases, notably the inflammation of Crohn’s

More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest appointments

  • TiGenix appoints Dr Marie Paule Richard TiGenix appoints Dr Marie Paule Richard

    in phase III trials for complex perianal fistulas in Crohn's disease.

  • Ex J&J VP joins board of Immune Ex J&J VP joins board of Immune

    Immune will benefit from Durrant's knowledged of the iundstry gained during time in roles such as worldwide VP at Johnson &Johnson and VP, Pharmacia until its acquisition by Pfizer. ... Its lead product candidate is bertilimumab, which is in clinical

  • Former Novartis president joins Qu Biologics Former Novartis president joins Qu Biologics

    His senior industry experience will support Qu Biologics' plans to advance the development of its investigational immunotherapies for treatments such as Crohn's disease. ... Bob Pelzer's wealth of leadership experience with Novartis and DuPont will be

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 13 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Quick links

Infographics

Multimedia